CHICAGO--(BUSINESS WIRE)--Dec 18, 2025-- Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today issued a statement on behalf of Cresco Labs CEO Charlie Bachtell following President Trump’s action to reschedule cannabis from a Schedule I to Schedule III substance under the Controlled Substances Act. “Today marks the most consequential moment in the history of U.S. cannabis. The decision to move cannabis from Schedule I to Schedule III will be a cultural turning point, acknowledging what millions of Americans already know: cannabis is medicine and deserves responsible, common-sense regulation.